Hypercalcemia of Malignancy
A life-threatening metabolic complication of advanced cancer causing very high calcium levels due to tumor-secreted hormones (PTHrP) or bone metastases.
Emergency Management: Severe hypercalcemia (Ca > 14 mg/dL) with neurologic/cardiac compromise requires ICU admission, massive fluid resuscitation, calcitonin, and potentially hemodialysis against a low-calcium bath if renal failure prevents fluid administration.
Hypercalcemia of malignancy (HCM) is a severe, life-threatening paraneoplastic syndrome or direct complication of advanced cancer. It is characterized by dangerously elevated serum calcium levels resulting from tumor-driven bone resorption and renal calcium retention.
Detailed Overview
HCM is the most common life-threatening metabolic emergency in oncology, occurring in up to 30% of cancer patients at some point in their disease course. It implies advanced disease and a very poor prognosis, with median survival often measured in weeks to months. The most frequent mechanism is humoral hypercalcemia mediated by the tumor's secretion of Parathyroid Hormone-related Protein (PTHrP), classically seen in squamous cell carcinomas. Other mechanisms include osteolytic bone metastases and extrarenal calcitriol production. The rapid rise in calcium severely disrupts neurological, cardiovascular, and renal function, leading to coma and cardiac arrest if not aggressively managed with IV hydration and osteoclast inhibitors.
Epidemiology & Demographics
Incidence: Affects 20-30% of patients with cancer during their illness. Associated Cancers: Most commonly seen in multiple myeloma, breast cancer, lung cancer (squamous cell), and renal cell carcinoma. Age distribution: Parallels the incidence of the underlying malignancies (mostly older adults).
Etiological Mechanism
Disruption of normal calcium homeostasis by malignant cells through humoral factors or direct bone destruction.
Primary Causes
Humoral Hypercalcemia of Malignancy (80%): Tumor secretion of PTHrP (Squamous cell lung/head/neck, Renal, Breast)
Osteolytic Metastases (20%): Direct bone destruction by tumor cells releasing local cytokines like RANKL (Breast, Multiple Myeloma)
Calcitriol Secretion (<1%): Tumor expressing 1-alpha-hydroxylase producing active Vitamin D (Lymphomas)
In Humoral Hypercalcemia of Malignancy (the most common form), the primary tumor secretes PTHrP. PTHrP shares structural homology with the N-terminus of normal parathyroid hormone (PTH) and binds to the same PTH-1 receptor in bones and kidneys. In the bone, PTHrP heavily upregulates RANKL expression on osteoblasts, which activates osteoclasts, leading to massive, uncoupled bone resorption and calcium release into the blood. In the kidney, PTHrP increases distal tubular reabsorption of calcium. Crucially, the extreme calcium load causes nephrogenic diabetes insipidus (blocking ADH action), leading to profound polyuria. The resulting severe dehydration shrinks the intravascular volume, drastically reducing the GFR. This 'calcium-induced volume depletion' further prevents the kidneys from excreting the excess calcium, creating a rapid, lethal positive feedback loop.
Diagnostic Criteria & Guidelines
Diagnosis requires an elevated serum corrected calcium (>10.5 mg/dL) or ionized calcium, accompanied by a suppressed intact PTH level (<20 pg/mL) in a patient with known or suspected malignancy. Calcium must be corrected for hypoalbuminemia (Corrected Ca = Total Ca + 0.8 * (4 - Albumin)).
Immediate, aggressive IV hydration with Normal Saline (0.9% NaCl) at 200-300 mL/hr to restore intravascular volume and promote renal calcium excretion. Once hydrated, administer an IV Bisphosphonate (e.g., Zoledronic acid 4 mg IV over 15 minutes OR Pamidronate 90 mg IV over 2 hours). Note: Bisphosphonates take 48-72 hours to achieve peak effect.
Second-Line & Adjunctive Therapy
Subcutaneous Calcitonin (4 IU/kg every 12 hours) works rapidly within hours to lower calcium via tachyphylaxis, bridging the gap until bisphosphonates work. Denosumab (120 mg SC) is used for bisphosphonate-refractory hypercalcemia. For calcitriol-mediated hypercalcemia (lymphoma), use Glucocorticoids (Prednisone 40-60 mg daily).
Surgical & Procedural Management
None specifically for the hypercalcemia. Treatment focuses on medical management and eventually treating the underlying tumor.
Patient Counseling & Advice
Since this syndrome usually occurs in advanced, end-stage cancer, discussions must heavily involve prognosis and goals of care. Discuss that while the IV fluids will wake the patient up and relieve symptoms temporarily, the hypercalcemia will likely return unless the underlying cancer responds to chemotherapy.
Follow-Up & Monitoring Schedule
Check serum calcium, albumin, phosphorus, and renal function every 12-24 hours during acute treatment. Long-term, monitor calcium levels monthly. Denosumab or Zoledronic acid may be given monthly to prevent recurrence.
Preventive Strategies
Routine use of bone-modifying agents (monthly Zoledronic acid or Denosumab) in patients with known bone metastases to prevent skeletal-related events, including hypercalcemia.
Extremely poor. The onset of HCM usually signifies end-stage disease. Without effective antineoplastic therapy to target the underlying tumor, the median survival from the onset of HCM is approximately 1 to 3 months.